Adverum Biotechnologies Inc - Understand $advm stock

$ADVM Market Cap: $151.8 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$99.86M

TTM

Current Assets

$179.4M

Q2 2024

Current Liabilities

$22.46M

Q2 2024

Current Ratio

798.8%

Q2 2024

Total Assets

$253.8M

Q2 2024

Total Liabilities

$85.77M

Q2 2024

Book Value

$168.0M

Q2 2024

Cash

$127.3M

Q2 2024

P/E

-1.521

Sep 17, 2024 EST

Free Cash Flow

-$89.12M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$3.600M	$0.00	$7.500M	$0.00	$250.0K	$1.612M	$1.849M	$1.460M	$2.319M	$572.0K	$480.0K	$30.00K
YoY Change		-100.0%		-100.0%	-84.49%	-12.82%	26.64%	-37.04%	305.42%	19.17%	1500.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$3.600M	$0.00	$7.500M	$0.00	$250.0K	$1.612M	$1.849M	$1.460M	$2.319M	$572.0K	$480.0K	$30.00K
Cost Of Revenue						$100.0K	$500.0K
Gross Profit						$1.512M	$1.349M
Gross Profit Margin						93.8%	72.96%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Selling, General & Admin	$49.72M	$55.76M	$63.34M	$44.64M	$28.38M	$24.56M	$20.86M	$24.36M	$22.11M	$8.000M	$1.780M	$540.0K
YoY Change	-10.84%	-11.97%	41.89%	57.29%	15.55%	17.74%	-14.37%	10.18%	176.38%	349.44%	229.63%
% of Gross Profit						1624.34%	1546.33%
Research & Development	$77.68M	$99.28M	$89.18M	$73.31M	$40.42M	$50.13M	$60.00K	$8.000K	$25.46M	$16.98M	$2.151M	$1.310M
YoY Change	-21.76%	11.32%	21.65%	81.37%	-19.38%	83455.0%	650.0%	-99.97%	49.99%	689.21%	64.2%
% of Gross Profit						3315.67%	4.45%
Depreciation & Amortization	$5.644M	$6.528M	$4.645M	$4.160M	$1.570M	$1.750M	$2.100M	$1.600M	$810.0K	$162.0K	$26.00K	$1.000K
YoY Change	-13.54%	40.54%	11.66%	164.97%	-10.29%	-16.67%	31.25%	97.53%	400.0%	523.08%	2500.0%
% of Gross Profit						115.74%	155.67%
Operating Expenses	$127.4M	$157.1M	$153.6M	$118.0M	$68.80M	$79.69M	$60.00K	$8.000K	$50.14M	$24.97M	$3.934M	$1.846M
YoY Change	-18.93%	2.29%	30.24%	71.45%	-13.67%	132721.67%	650.0%	-99.98%	100.78%	534.82%	113.11%
Operating Profit	-$124.0M	-$157.1M	-$146.1M	-$118.0M	-$68.55M	-$78.08M	-$58.85M		-$47.82M	-$24.40M	-$3.454M	-$1.816M
YoY Change	-21.09%	7.54%	23.88%	72.08%	-12.21%	32.68%			95.98%	606.49%	90.2%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Interest Expense								$0.00	$0.00	$18.00K	$73.00K	$8.000K
YoY Change									-100.0%	-75.34%	812.5%
% of Operating Profit
Other Income/Expense, Net	$5.748M	$2.673M	$582.0K	$1.557M	$4.059M	$4.204M	$2.700M	$762.0K	$370.0K	-$1.002M	-$1.822M	$5.000K
YoY Change	115.04%	359.28%	-62.62%	-61.64%	-3.45%	55.7%	254.33%	105.95%	-136.93%	-45.01%	-36540.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Pretax Income	-$118.2M	-$154.5M	-$145.5M	-$116.4M	-$64.49M	-$73.88M	-$56.15M	-$114.5M	-$47.45M	-$25.40M	-$5.276M	-$1.051M
YoY Change	-23.45%	6.13%	25.04%	80.49%	-12.71%	31.58%	-50.97%	141.34%	86.79%	381.5%	402.0%
Income Tax	-$1.078M	$74.00K	$0.00	$1.114M	$0.00	-$1.250M	$0.00	-$775.0K	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$117.2M	-$154.5M	-$145.5M	-$117.5M	-$64.49M	-$72.63M	-$56.15M	-$113.7M	-$47.45M	-$25.40M	-$5.276M	-$1.811M
YoY Change	-24.18%	6.18%	23.86%	82.22%	-11.21%	29.35%	-50.64%	139.7%	86.79%	381.5%	191.33%
Net Earnings / Revenue	-3254.58%		-1940.53%		-25794.4%	-4505.4%	-3036.61%	-7790.89%	-2046.27%	-4441.26%	-1099.17%	-6036.67%
Basic Earnings Per Share	-$1.16	-$1.56	-$1.48	-$1.38
Diluted Earnings Per Share	-$1.16	-$1.56	-$1.48	-$1.38	-$1.006M	-$1.183M	-$1.286M	-$3.138M	-$1.862M	-$2.180M	-$247.2K	-$84.74K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Cash & Short-Term Investments	$96.53M	$185.6M	$305.2M	$429.7M	$166.0M	$205.1M	$190.5M	$222.2M	$259.1M	$159.4M	$600.0K	$400.0K
YoY Change	-47.99%	-39.19%	-28.98%	158.86%	-19.06%	7.66%	-14.27%	-14.24%	62.55%	26466.67%	50.0%
Cash & Equivalents	$75.00M	$68.43M	$34.20M	$62.40M	$65.90M	$154.9M	$70.50M	$222.2M	$221.3M	$159.4M	$600.0K	$400.0K
Short-Term Investments	$21.53M	$117.2M	$271.0M	$367.3M	$100.1M	$50.10M	$120.0M		$37.70M
Other Short-Term Assets	$6.247M	$5.006M	$6.248M	$4.700M	$9.800M	$3.700M	$3.300M	$2.200M	$1.500M	$900.0K	$300.0K	$0.00
YoY Change	24.79%	-19.88%	32.94%	-52.04%	164.86%	12.12%	50.0%	46.67%	66.67%	200.0%
Inventory
Prepaid Expenses
Receivables										$0.00	$0.00	$0.00
Other Receivables										$0.00	$0.00	$0.00
Total Short-Term Assets	$102.8M	$190.6M	$317.1M	$434.4M	$175.9M	$208.8M	$193.7M	$225.3M	$261.0M	$160.3M	$800.0K	$400.0K
YoY Change	-46.08%	-39.9%	-26.99%	146.96%	-15.76%	7.8%	-14.03%	-13.68%	62.82%	19937.5%	100.0%
Property, Plant & Equipment	$67.03M	$113.9M	$119.1M	$47.10M	$45.80M	$3.600M	$3.000M	$4.200M	$3.200M	$1.100M	$100.0K	$0.00
YoY Change	-41.13%	-4.37%	152.78%	2.84%	1172.22%	20.0%	-28.57%	31.25%	190.91%	1000.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.207M	$3.916M	$2.753M	$1.000M	$1.000M	$1.200M	$100.0K	$100.0K	$100.0K	$500.0K	$200.0K	$0.00
YoY Change	-18.11%	42.24%	175.3%	0.0%	-16.67%	1100.0%	0.0%	0.0%	-80.0%	150.0%
Total Long-Term Assets	$70.24M	$117.8M	$122.6M	$48.20M	$46.80M	$4.700M	$8.200M	$9.300M	$3.300M	$1.600M	$300.0K	$0.00
YoY Change	-40.36%	-3.92%	154.32%	2.99%	895.74%	-42.68%	-11.83%	181.82%	106.25%	433.33%
Total Assets	$173.0M	$308.4M	$439.7M	$482.6M	$222.7M	$213.5M	$201.9M	$234.6M	$264.3M	$161.9M	$1.100M	$400.0K
YoY Change
Accounts Payable	$1.921M	$2.238M	$1.387M	$2.800M	$4.100M	$1.700M	$1.700M	$1.500M	$600.0K	$1.000M	$800.0K	$500.0K
YoY Change	-14.16%	61.36%	-50.46%	-31.71%	141.18%	0.0%	13.33%	150.0%	-40.0%	25.0%	60.0%
Accrued Expenses	$22.89M	$29.75M	$18.62M	$18.10M	$15.30M	$8.800M	$7.000M	$6.500M	$4.000M	$3.700M	$400.0K	$300.0K
YoY Change	-23.06%	59.84%	2.85%	18.3%	73.86%	25.71%	7.69%	62.5%	8.11%	825.0%	33.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$24.91M	$32.25M	$21.32M	$20.90M	$19.40M	$10.70M	$10.70M	$9.900M	$6.600M	$5.500M	$1.200M	$800.0K
YoY Change	-22.74%	51.25%	2.01%	7.73%	81.31%	0.0%	8.08%	50.0%	20.0%	358.33%	50.0%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$100.0K	$500.0K
YoY Change										-100.0%	-80.0%
Other Long-Term Liabilities	$64.63M	$94.61M	$102.2M	$27.30M	$28.40M	$1.600M	$6.000M	$7.800M	$5.200M	$7.000M	$100.0K	$0.00
YoY Change	-31.69%	-7.45%	274.44%	-3.87%	1675.0%	-73.33%	-23.08%	50.0%	-25.71%	6900.0%
Total Long-Term Liabilities	$64.63M	$94.61M	$102.2M	$27.30M	$28.40M	$1.600M	$6.000M	$7.800M	$5.200M	$7.000M	$200.0K	$500.0K
YoY Change	-31.69%	-7.45%	274.44%	-3.87%	1675.0%	-73.33%	-23.08%	50.0%	-25.71%	3400.0%	-60.0%
Total Liabilities	$89.54M	$126.9M	$123.5M	$48.20M	$47.80M	$12.30M	$17.90M	$19.00M	$11.70M	$12.40M	$1.300M	$1.400M
YoY Change	-29.41%	2.68%	156.31%	0.84%	288.62%	-31.28%	-5.79%	62.39%	-5.65%	853.85%	-7.14%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020
Basic Shares Outstanding	100.8M shares	99.25M shares	98.04M shares	85.15M shares
Diluted Shares Outstanding	100.8M shares	99.25M shares	98.04M shares	85.15M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $151.85 Million

About Adverum Biotechnologies Inc

Adverum Biotechnologies Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Redwood City, California and currently employs 121 full-time employees. The company went IPO on 2014-07-31. Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The firm discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. The company also developing an early-stage pipeline of gene therapy programs.

Industry: Biological Products, (No Diagnostic Substances) Peers: Bioxytran Inc Elutia Inc Checkpoint Therapeutics Inc CytomX Therapeutics Inc Leap Therapeutics Inc Eliem Therapeutics Inc Galectin Therapeutics Inc Q32 Bio Inc Immunic Inc